Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 516

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1A
Chunk 516
---
 that any fundraising will be achieved on commercially reasonable terms, if
at all.

As
of the date of filing this Annual Report, the Company will continue to generate losses and have insufficient cash and cash equivalents
on hand to support its operations for at least the 12 months following the date the financial statements are issued.  These factors raise substantial doubt about the Company’s ability to continue as a going concern for
a period of twelve months from the issuance date of this report. Management cannot provide assurance that the Company will ultimately
achieve profitable operations or become cash flow positive or raise additional debt and/or equity capital. The Company is seeking to
raise capital through additional debt and/or equity financings to fund our operations in the future. If the Company is unable to raise
additional capital or secure additional lending in the near future, management expects that the Company will need to curtail its operations.
These financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and
classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

    F-10

Telomir
                                            Pharmaceuticals, Inc.

notes
to the financial statements

DECEMBER
31, 2024 and 2023

Note
3. License agreement, related party

The
Company licenses the U.S. patent rights for the use of Telomir-1 in human applications from MIRALOGX, LLC (“MIRALOGX”), an
intellectual property development and holding company.

On
August 11, 2023, (the “Effective Date”), the Company and MIRALOGX entered into an Amended and Restated Exclusive License
Agreement, under which the Company has the exclusive perpetual right and license under the above-described patent rights to make, have
made, use, and sell “Licensed Products” in the U.S. for human uses and preclinical studies and activities of any kind conducted
in furtherance of obtaining regulatory approval or commercialization for human uses (the “MIRALOGX License Agreement”). On
November 10, 2023, the Company and MIRALOGX entered into the Amendment No. 1 to the Amended and Restated License Agreement, pursuant
to which the field of use relating to the license was amended to include therapeutic treatments and other medical or health uses in animals,
in addition to humans, and related preclinical studies and activities conducted in furtherance of obtaining regulatory approval for and